PeakShares LLC Takes $1.06 Million Position in Thermo Fisher Scientific Inc. $TMO

PeakShares LLC bought a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 1,836 shares of the medical research company’s stock, valued at approximately $1,064,000.

Several other large investors have also recently bought and sold shares of the company. J. Stern & Co. LLP increased its holdings in shares of Thermo Fisher Scientific by 58,006.4% in the fourth quarter. J. Stern & Co. LLP now owns 31,509,332 shares of the medical research company’s stock worth $18,258,082,000 after purchasing an additional 31,455,105 shares during the period. Norges Bank purchased a new position in Thermo Fisher Scientific during the fourth quarter worth about $3,072,744,000. Auto Owners Insurance Co increased its stake in Thermo Fisher Scientific by 57,845.0% in the 4th quarter. Auto Owners Insurance Co now owns 2,427,896 shares of the medical research company’s stock worth $1,406,844,000 after acquiring an additional 2,423,706 shares during the last quarter. T. Rowe Price Investment Management Inc. raised its holdings in shares of Thermo Fisher Scientific by 2,183.2% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,328,845 shares of the medical research company’s stock valued at $770,000,000 after acquiring an additional 1,270,643 shares in the last quarter. Finally, Wellington Management Group LLP boosted its position in shares of Thermo Fisher Scientific by 88.9% during the 3rd quarter. Wellington Management Group LLP now owns 2,699,460 shares of the medical research company’s stock valued at $1,309,292,000 after acquiring an additional 1,270,191 shares during the last quarter. 89.23% of the stock is owned by institutional investors.

Thermo Fisher Scientific Stock Up 0.3%

Shares of TMO opened at $465.98 on Friday. Thermo Fisher Scientific Inc. has a 1 year low of $390.50 and a 1 year high of $643.99. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.53 and a quick ratio of 1.15. The stock has a 50 day simple moving average of $476.59 and a two-hundred day simple moving average of $523.32. The firm has a market cap of $173.17 billion, a P/E ratio of 25.62, a P/E/G ratio of 2.06 and a beta of 0.88.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Thursday, April 23rd. The medical research company reported $5.44 EPS for the quarter, topping the consensus estimate of $5.25 by $0.19. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The firm had revenue of $11.01 billion for the quarter, compared to the consensus estimate of $10.86 billion. During the same period last year, the firm posted $5.15 earnings per share. The business’s revenue was up 6.2% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. On average, analysts forecast that Thermo Fisher Scientific Inc. will post 24.85 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, July 15th. Shareholders of record on Monday, June 15th will be given a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a yield of 0.4%. The ex-dividend date is Monday, June 15th. Thermo Fisher Scientific’s dividend payout ratio is presently 10.34%.

Analysts Set New Price Targets

TMO has been the topic of several research analyst reports. Wells Fargo & Company decreased their price objective on shares of Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating on the stock in a research report on Friday, May 8th. KeyCorp reissued an “overweight” rating on shares of Thermo Fisher Scientific in a research note on Tuesday, May 26th. Stifel Nicolaus decreased their price target on shares of Thermo Fisher Scientific from $700.00 to $600.00 and set a “buy” rating on the stock in a report on Friday, April 24th. Piper Sandler began coverage on shares of Thermo Fisher Scientific in a report on Thursday, June 11th. They set a “neutral” rating and a $510.00 price objective for the company. Finally, Wall Street Zen lowered shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Saturday, May 9th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat.com, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and a consensus price target of $608.95.

Insider Activity

In other news, COO Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction dated Monday, April 27th. The stock was sold at an average price of $462.66, for a total transaction of $185,064.00. Following the transaction, the chief operating officer directly owned 25,051 shares of the company’s stock, valued at approximately $11,590,095.66. This trade represents a 1.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.